(AZN) AstraZeneca - Ratings and Ratios
Cancer, Cardiovascular, Respiratory, Rare Diseases, Vaccines
AZN EPS (Earnings per Share)
AZN Revenue
Description: AZN AstraZeneca
AstraZeneca PLC is a leading biopharmaceutical company with a diverse portfolio of prescription medicines across various therapeutic areas, including oncology, cardiovascular, renal and metabolism, respiratory & immunology, vaccines and immune, and rare diseases. The companys product pipeline is robust, with a range of established brands such as Tagrisso, Imfinzi, and Farxiga, as well as newer additions like Enhertu and Ultomiris.
From a strategic perspective, AstraZeneca has demonstrated a commitment to innovation through partnerships and collaborations, including a notable agreement with Tempus to develop a multimodal foundation model in oncology. Additionally, the companys collaboration with IonQ, Inc. to leverage quantum computing in computational chemistry workflow highlights its willingness to explore cutting-edge technologies. Key Performance Indicators (KPIs) such as Research and Development (R&D) expenditure as a percentage of revenue, and the success rate of its pipeline candidates, will be crucial in assessing the companys long-term growth prospects.
AstraZenecas global presence, with operations in the United Kingdom, the United States, Europe, and Asia, positions it well to capitalize on emerging opportunities in the biopharmaceutical market. The companys ability to serve primary and specialty care physicians through distributors and local representative offices is a key strength. To further evaluate the companys performance, metrics such as revenue growth rate, operating margin, and return on equity (RoE) of 19.18% will be closely monitored.
From a valuation perspective, AstraZenecas Price-to-Earnings (P/E) ratio of 27.89 and Forward P/E of 15.41 suggest a relatively stable valuation. The companys Market Capitalization of $215.9 billion USD underscores its significant presence in the global biopharmaceutical market. To gain a deeper understanding of the companys stock performance, metrics such as dividend yield, beta, and trading volume will be analyzed in conjunction with the provided technical data.
Additional Sources for AZN Stock
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle
AZN Stock Overview
Market Cap in USD | 215,915m |
Sector | Healthcare |
Industry | Drug Manufacturers - General |
GiC Sub-Industry | Pharmaceuticals |
IPO / Inception | 1993-05-12 |
AZN Stock Ratings
Growth Rating | 30.5 |
Fundamental | 73.8 |
Dividend Rating | 46.5 |
Rel. Strength | -1.19 |
Analysts | 4.42 of 5 |
Fair Price Momentum | 67.42 USD |
Fair Price DCF | 61.75 USD |
AZN Dividends
Dividend Yield 12m | 2.17% |
Yield on Cost 5y | 2.92% |
Annual Growth 5y | 1.19% |
Payout Consistency | 96.4% |
Payout Ratio | 44.7% |
AZN Growth Ratios
Growth Correlation 3m | 35.1% |
Growth Correlation 12m | -42.9% |
Growth Correlation 5y | 88.4% |
CAGR 5y | 5.77% |
CAGR/Max DD 5y | 0.21 |
Sharpe Ratio 12m | 0.93 |
Alpha | -17.95 |
Beta | 0.235 |
Volatility | 23.40% |
Current Volume | 3698.7k |
Average Volume 20d | 3687.4k |
Stop Loss | 67.2 (-3%) |
As of July 19, 2025, the stock is trading at USD 69.26 with a total of 3,698,651 shares traded.
Over the past week, the price has changed by -3.55%, over one month by -2.41%, over three months by +2.47% and over the past year by -11.41%.
Yes, based on ValueRay´s Fundamental Analyses, AstraZeneca (NASDAQ:AZN) is currently (July 2025) a good stock to buy. It has a ValueRay Fundamental Rating of 73.81 and therefor a positive outlook according to the companies health.
Based on momentum, paid dividends and discounted-cash-flow analyses, the fair value of AZN is around 67.42 USD . This means that AZN is currently overvalued and has a potential downside of -2.66%.
AstraZeneca has received a consensus analysts rating of 4.42. Therefore, it is recommended to buy AZN.
- Strong Buy: 6
- Buy: 5
- Hold: 1
- Sell: 0
- Strong Sell: 0
According to our own proprietary Forecast Model, AZN AstraZeneca will be worth about 73 in July 2026. The stock is currently trading at 69.26. This means that the stock has a potential upside of +5.33%.
Issuer | Target | Up/Down from current |
---|---|---|
Wallstreet Target Price | 84.2 | 21.5% |
Analysts Target Price | 84.2 | 21.5% |
ValueRay Target Price | 73 | 5.3% |